Bumetanide - Only For Children Pharmaceuticals/Swedish Orphan Biovitrum

Drug Profile

Bumetanide - Only For Children Pharmaceuticals/Swedish Orphan Biovitrum

Alternative Names: Bumetanide - Only For Children Pharmaceuticals/Swedish Orphan Biovitrum (Sobi)

Latest Information Update: 17 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Only for Children Pharmaceuticals
  • Class Antihypertensives; Benzoic acids; Heart failure therapies; Sulfonamides
  • Mechanism of Action Ion pump modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Neonatal seizures

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 30 Aug 2011 Phase-I/II clinical trials in Neonatal seizures in Finland (IV)
  • 30 Aug 2011 Phase-I/II clinical trials in Neonatal seizures in Ireland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top